Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use
- PMID: 25635369
- DOI: 10.1016/j.yebeh.2014.12.020
Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use
Abstract
Purpose: This study aimed to compare health-care utilization and costs in patients treated with long-acting (LA) vs. short-acting (SA) antiepileptic drug (AED) monotherapy.
Methods: We conducted a cross-sectional study of claims from the OptumInsight™ database. Our analysis was restricted to adults diagnosed with epilepsy and who used AED monotherapy. Patients were excluded if they used >1 type of AED, had <9months of treatment, or had a treatment gap of >60days. Antiepileptic drugs were classified as LA or SA based on published data and expert opinion. Medical and pharmacy claims were used to estimate health-care utilization and costs, and baseline group differences were adjusted using multivariate analyses.
Results: There were 4058 (49.6%) LA AED users and 4122 (50.4%) SA AED users. Medication possession ratios (MPRs) were not significantly different between LA AED users and SA AED users (P=0.125). Long-acting AED users had lower mean overall health-care costs ($9757 vs. $12,689), lower epilepsy-related costs ($3539 vs. $5279), and lower rate of overall (8.8% vs. 10.9%) and epilepsy-related hospitalizations (5.7% vs. 7.6%) compared with SA AED users (all P<0.01). After adjusting for demographics and clinical characteristics, mean overall costs were lower by $686 and the mean epilepsy-related costs were lower by $894 in LA AED users.
Conclusion: Although MPRs were similar in LA AED and SA AED groups, patients treated with LA monotherapy had a lower economic burden compared with those treated with SA monotherapy, indicating that using AEDs with extended duration of action is associated with decreased health-care use and lower health-care costs.
Keywords: Adherence; Antiepileptic drugs; Cost analysis; Economics; Epilepsy; Medical care; Seizures.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.Epilepsy Behav. 2017 Nov;76:24-31. doi: 10.1016/j.yebeh.2017.08.039. Epub 2017 Sep 18. Epilepsy Behav. 2017. PMID: 28931473 Review.
-
Association between switching antiepileptic drug products and healthcare utilization: A systematic review.Epilepsy Behav. 2017 Aug;73:166-172. doi: 10.1016/j.yebeh.2017.05.010. Epub 2017 Jun 20. Epilepsy Behav. 2017. PMID: 28641169 Review.
-
Clinical and economic burden of breakthrough seizures.Epilepsy Behav. 2015 Oct;51:40-7. doi: 10.1016/j.yebeh.2015.06.013. Epub 2015 Aug 5. Epilepsy Behav. 2015. PMID: 26255884
-
Healthcare utilization and costs in children with stable and uncontrolled epilepsy.Epilepsy Behav. 2014 Mar;32:135-41. doi: 10.1016/j.yebeh.2014.01.016. Epub 2014 Feb 19. Epilepsy Behav. 2014. PMID: 24561658
-
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.Epilepsia. 2008 Mar;49(3):446-54. doi: 10.1111/j.1528-1167.2007.01414.x. Epub 2007 Nov 21. Epilepsia. 2008. PMID: 18031549
Cited by
-
Ketogenic Diet and Epilepsy.Nutrients. 2019 Oct 18;11(10):2510. doi: 10.3390/nu11102510. Nutrients. 2019. PMID: 31635247 Free PMC article. Review.
-
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.Hepatol Commun. 2017 May 23;1(5):439-452. doi: 10.1002/hep4.1049. eCollection 2017 Jul. Hepatol Commun. 2017. PMID: 29404471 Free PMC article.
-
Association between addressing antiseizure drug side effects and patient-reported medication adherence in epilepsy.Patient Prefer Adherence. 2016 Oct 31;10:2197-2207. doi: 10.2147/PPA.S119973. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27826186 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous